Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 9ruxolitinib 7Azacitidine 7fludarabine phosphate 6Whole-Body Irradiation 6Peripheral Blood Stem Cell Transplantation 6Mycophenolic Acid 6navitoclax 5fludarabine 5Therapeutics 5Busulfan 5ponatinib 4Melphalan 4Tacrolimus 3Stem Cell Transplantation 3Patient Reported Outcome Measures 3Mesna 3Immunoenzyme Techniques 3Flow Cytometry 3Cyclosporine 3Clofarabine 3Antilymphocyte Serum 3vosaroxin 2trametinib 2liposomal amphotericin B 2dabrafenib 2Watchful Waiting 2Transplantation 2Sirolimus 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × alvocidib × Myeloid × Clear all
NCT03593915 2023-11-09

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Sumitomo Pharma America, Inc.

Phase 1/2 Terminated
20 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡